Article
A niche driven mechanism determines response and a mutation-independent therapeutic approach for myeloid malignancies.
Cancer cell - 9 Jun 2025
Mosialou Ioanna, Ali Abdullah M, Labella Rossella, Bisikirska Brygida, Cuesta-Dominguez Alvaro, Vgenopoulou Paraskevi, Reyes Ismarc, Rao Sanjana M, Wang Anqi, Luo Na, Galan-Diez Marta, Zhao Junfei, Chernak Brian J, Bewersdorf Jan Philipp, Fukasawa Kazuya, Su Jiayu, Higa Jason, Adams Rachel A, Corper Adam L, Pampou Sergey, Woods Catherine M, Fan Xiaomin, Shah Roshan P, Feldstein Julie, Liu Na, Liang Cui, Heiblig Maël, Kornblau Steven, Garcia-Manero Guillermo, Berman Ellin, Jurcic Joseph G, Rabadan Raul, Raza Azra, Kousteni Stavroula
Abstract excerpt
Myeloid cancers such as myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) remain resistant to standard of care (SOC) and targeted therapies. In this study, we demonstrate that responsiveness to therapy is associated with activation of β-catenin-JAG1 in osteoblastic cells of patients treated with all-trans-retinoic acid (ATRA). ATRA suppresses β-catenin activity in patients and leukemic mice....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.